A similar relationship between mutation clearance and treatment response has been observed in studies of isocitrate dehydrogenase (IDH) inhibitors in patients with IDH1‐ or IDH2‐mutated R/R AML.25, 26. The gene discussed is IDH2; the disease is acute myeloid leukemia.